Vantage Financial Partners, LLC Gilead Sciences, Inc. Transaction History

Vantage Financial Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$76.01 - $86.7 $6,536 - $7,456	86 Added 0.94%	9,249 $712,000
Q1 2023 May 08, 2023	BUY	$77.31 - $88.08 $49,942 - $56,899	646 Added 7.58%	9,163 $760,000
Q4 2022 Feb 08, 2023	SELL	$62.32 - $89.47 $369,432 - $530,378	-5,928 Reduced 41.04%	8,517 $731,000
Q3 2022 Oct 31, 2022	BUY	$59.54 - $68.01 $9,883 - $11,289	166 Added 1.16%	14,445 $9,000
Q2 2022 Aug 10, 2022	BUY	$57.72 - $65.01 $9,408 - $10,596	163 Added 1.15%	14,279 $883,000
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $10,020 - $12,556	173 Added 1.24%	14,116 $839,000
Q4 2021 Mar 03, 2022	BUY	$64.88 - $73.64 $904,621 - $1.03 Million	13,943 New	13,943 $1.01 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Vantage Financial Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Vantage Financial Partners, LLC with notifications on news.